Direkt zum Inhalt
Merck

SML3205

Sigma-Aldrich

Sitagliptin

≥98% (HPLC)

Synonym(e):

(2R)-4-Oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine, (3R)-3-Amino-1-[5,6-dihydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a ]pyrazin-7(8H )-yl]-4-(2,4,5-trifluorophenyl)-1-butanone,, MK 0431 free base, MK 431 free base, MK-0431 free base, MK-431 free base, MK0431 free base, MK431 free base

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise


About This Item

Empirische Formel (Hill-System):
C16H15F6N5O
CAS-Nummer:
Molekulargewicht:
407.31
MDL-Nummer:
UNSPSC-Code:
51111800
NACRES:
NA.77

Qualitätsniveau

Assay

≥98% (HPLC)

Form

powder

Optische Aktivität

[α]/D -17 to -23°, c = 0.5 in chloroform-d

Farbe

white to beige

Löslichkeit

DMSO: 2 mg/mL, clear

Lagertemp.

−20°C

SMILES String

FC(F)(F)c1[n]2c(nn1)CN(CC2)C(=O)C[C@H](N)Cc3c(cc(c(c3)F)F)F

InChI

1S/C16H15F6N5O/c17-10-6-12(19)11(18)4-8(10)3-9(23)5-14(28)26-1-2-27-13(7-26)24-25-15(27)16(20,21)22/h4,6,9H,1-3,5,7,23H2/t9-/m1/s1

InChIKey

MFFMDFFZMYYVKS-SECBINFHSA-N

Biochem./physiol. Wirkung

Orally active, potent and selective dipeptidyl peptidase IV (DPP-IV; DPP4) inhibitor that improves glucose tolerance in vivo.
Sitagliptin is an orally active, potent and selective dipeptidyl peptidase IV (DPP4; DPP-IV) inhibitor (IC50 = 18 nM) with excellent selectivity over other proline-selective peptidases (IC50 = 48 μM/DPP8, >100 μM/DPP9 & QPP). Sitagliptin improves glucose tolerance in lean mice (23% and 55% reduction of blood glucose post 5 g dextrose/kg with 0.1 or 3 mg Sitagliptin/kg p.o. 60 min prior to dextrose challenge) and in DIO mice (68% and 90% reduction of blood glucose post 2 g dextrose/kg with 0.3 or 3 mg Sitagliptin/kg p.o.) as a result of DPP-IV inhibition and upregulated GLP-1 level in blood in vivo.

Piktogramme

Health hazardExclamation mark

Signalwort

Warning

H-Sätze

Gefahreneinstufungen

Eye Irrit. 2 - STOT RE 2

Zielorgane

Liver

Lagerklassenschlüssel

11 - Combustible Solids

WGK

WGK 3

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable


Hier finden Sie alle aktuellen Versionen:

Analysenzertifikate (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Dokumente section.

Wenn Sie Hilfe benötigen, wenden Sie sich bitte an Kundensupport

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Heba A Habib et al.
Life sciences, 278, 119624-119624 (2021-05-19)
Diabetic nephropathy, a major threat to diabetic patients, is considered as the main reason for end-stage renal disease. Fortunately, incretin-based therapy has been aroused as considerable source to attenuate diabetic renal damage. This study aimed to investigate whether superior protective
Mohamed Abouelkheir
Current molecular pharmacology (2021-06-03)
We previously tested two angiotensin-converting enzyme (ACE) inhibitors and two dipeptidyl peptidase-4 (DPP-4) inhibitors for dual enzyme inhibitory effect. Only two DPP-4 inhibitors, linagliptin and sitagliptin, were able to inhibit ACE. In the present study, we investigated if other inhibitors
Yossra Ahmed et al.
Journal of diabetes and metabolic disorders, 20(1), 551-560 (2021-07-06)
Emerging evidence suggests that mesenchymal stem cells (MSCs) have many anti-inflammatory and regenerative properties, which makes it a suitable candidate for the treatment of many diseases including metabolic syndrome (MetS). However, a major difficulty with stem cell therapy is to

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.